Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
6abc News8d
Recognizing EOE, a digestive disorder probably triggered by an allergic reaction
Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...
Medpage Today on MSN14d
Novel Drug Improved Symptoms in Eosinophilic Esophagitis
The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in ...
Medscape8d
Eosinophilic Esophagitis: the newest esophageal inflammatory disease
Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...
Business Insider20h
Eupraxia reports data from RESOLVE Phase 1b/2a trial
Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...
Seeking Alpha3h
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...
Pharmabiz6d
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...
Hosted on MSN5d
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...
Daily6d
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis
Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...
Medical Xpress20d
Among allergic conditions, food allergy found to have highest risk of developing eosinophilic esophagitis
Citation: Among allergic conditions, food allergy found to have highest risk of developing eosinophilic esophagitis (2024, October 24) retrieved 11 November 2024 from https://medicalxpress.com ...
Medscape18d
Eosinophilic Esophagitis: the newest esophageal inflammatory disease
The other authors declared no competing interests. Eosinophilic esophagitis is a clinicopathological disease characterized by a wide variety of GERD-like symptoms, dysphagia and vomiting that ...